← FDA DRUG APPROVALS

FDA NDA · NDA020572

BUPHENYL

sodium phenylbutyrate

Sponsor: HORIZON THERAP US

APPLICATION
NDA020572
TYPE
NDA
ORIGINAL APPROVAL
1996-05-13
LATEST ACTION
2022-07-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

BUPHENYL · ReferenceDiscontinued
SODIUM PHENYLBUTYRATE 500MG · TABLET · ORAL

Approval history

2022-07-29Labeling · Supplement 25 · standardLetterAP
2015-10-06Manufacturing (CMC) · Supplement 21 · priorityAP
2013-08-02Manufacturing (CMC) · Supplement 20 · priorityAP
2009-03-31Labeling · Supplement 16 · standardLabelAP
1998-10-09Labeling · Supplement 2 · standardAP
1996-11-07Manufacturing (CMC) · Supplement 1 · priorityAP
1996-05-13Type 3 - New Dosage Form · Original · priorityAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →